Photocure ASA: Update on Regulatory Classification for OAY Equipment
This information was shared with Photocure as part of its ongoing dialogue with the FDA, following the Reclassification Petition submitted by Karl Storz SE & Co. KG and addressed in Photocure's press release of
For further information, please contact:
President and CEO
Photocure ASA
Email: [email protected]
CFO
Photocure ASA
Tel: +47 45055000
Email: [email protected]
Vice President Investor Relations
Tel: +17176815072
Email: [email protected]
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (
Tel: +47 91540000
Email: [email protected]
About Photocure
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Tolv Hillestad, Photocure ASA, on
This information was brought to you by Cision http://news.cision.com.
The following files are available for download:
View original content:https://www.prnewswire.com/news-releases/photocure-asa-update-on-regulatory-classification-for-oay-equipment-302740263.html
SOURCE Photocure
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
- Clarins Lights Up the Austin Skyline with an Immersive Celebration of Skin Longevity
- Polygon Price Prediction: German Banks Add POL as Remittix Pairs Its $0.28 Entry With a November Launch Date
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share